$68.62
0.891.31%
At close: -
$69.09
0.470.68%
After Hours: Apr 11, 6:01 PM EDT
Comments
Loading...
Corcept Therapeutics Analyst Ratings and Price Targets | NASDAQ:CORT | Benzinga
Corcept Therapeutics Inc has a consensus price target of $92.71 based on the ratings of 7 analysts. The high is $150 issued by Truist Securities on March 31, 2025. The low is $22 issued by Jefferies on February 15, 2023. The 3 most-recent analyst ratings were released by Piper Sandler, Canaccord Genuity, and Truist Securities on April 3, 2025, April 1, 2025, and March 31, 2025, respectively. With an average price target of $141 between Piper Sandler, Canaccord Genuity, and Truist Securities, there's an implied 104.08% upside for Corcept Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Piper Sandler
Canaccord Genuity
Truist Securities
HC Wainwright & Co.
Truist Securities
1calculated from analyst ratings
Analyst Ratings for Corcept Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/03/2025 | Buy Now | 89.61% | Piper Sandler | David Amsellem69% | $128 → $131 | Maintains | Overweight | Get Alert |
| 04/01/2025 | Buy Now | 105.53% | Canaccord Genuity | Edward Nash61% | $130 → $142 | Maintains | Buy | Get Alert |
| 03/31/2025 | Buy Now | 117.11% | Truist Securities | Joon Lee75% | $76 → $150 | Maintains | Buy | Get Alert |
| 03/31/2025 | Buy Now | 117.11% | HC Wainwright & Co. | Swayampakula Ramakanth47% | $115 → $150 | Maintains | Buy | Get Alert |
| 02/27/2025 | Buy Now | 12.9% | Piper Sandler | David Amsellem69% | $67 → $78 | Maintains | Overweight | Get Alert |
| 02/27/2025 | Buy Now | 66.45% | HC Wainwright & Co. | Swayampakula Ramakanth47% | $115 → $115 | Reiterates | Buy → Buy | Get Alert |
| 02/11/2025 | Buy Now | 66.45% | HC Wainwright & Co. | Swayampakula Ramakanth47% | $80 → $115 | Maintains | Buy | Get Alert |
| 02/07/2025 | Buy Now | 15.79% | HC Wainwright & Co. | Swayampakula Ramakanth47% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 01/30/2025 | Buy Now | 88.16% | Canaccord Genuity | Edward Nash61% | $78 → $130 | Maintains | Buy | Get Alert |
| 10/31/2024 | Buy Now | 15.79% | HC Wainwright & Co. | Swayampakula Ramakanth47% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 10/18/2024 | Buy Now | 15.79% | HC Wainwright & Co. | Swayampakula Ramakanth47% | $45 → $80 | Maintains | Buy | Get Alert |
| 09/30/2024 | Buy Now | 10% | Truist Securities | Joon Lee75% | $65 → $76 | Maintains | Buy | Get Alert |
| 09/18/2024 | Buy Now | -3.03% | Piper Sandler | David Amsellem69% | $38 → $67 | Maintains | Overweight | Get Alert |
| 07/31/2024 | Buy Now | 12.9% | Canaccord Genuity | Edward Nash61% | $38 → $78 | Maintains | Buy | Get Alert |
| 07/30/2024 | Buy Now | -45% | Canaccord Genuity | Edward Nash61% | $38 → $38 | Maintains | Buy | Get Alert |
| 07/30/2024 | Buy Now | -45% | Piper Sandler | David Amsellem69% | $35 → $38 | Maintains | Overweight | Get Alert |
| 07/30/2024 | Buy Now | -34.87% | HC Wainwright & Co. | Swayampakula Ramakanth47% | $40 → $45 | Maintains | Buy | Get Alert |
| 07/01/2024 | Buy Now | -49.34% | Piper Sandler | David Amsellem69% | $35 → $35 | Reiterates | Overweight → Overweight | Get Alert |
| 06/17/2024 | Buy Now | -5.92% | Truist Securities | Joon Lee75% | $65 → $65 | Maintains | Buy | Get Alert |
| 06/04/2024 | Buy Now | -5.92% | Truist Securities | Joon Lee75% | $44 → $65 | Reiterates | Buy → Buy | Get Alert |
| 05/29/2024 | Buy Now | -42.1% | HC Wainwright & Co. | Swayampakula Ramakanth47% | $40 → $40 | Reiterates | Buy → Buy | Get Alert |
| 05/02/2024 | Buy Now | -42.1% | HC Wainwright & Co. | Swayampakula Ramakanth47% | $38 → $40 | Maintains | Buy | Get Alert |
| 05/02/2024 | Buy Now | -36.31% | Truist Securities | Joon Lee75% | $42 → $44 | Maintains | Buy | Get Alert |
| 04/23/2024 | Buy Now | -45% | HC Wainwright & Co. | Swayampakula Ramakanth47% | $38 → $38 | Reiterates | Buy → Buy | Get Alert |
| 02/16/2024 | Buy Now | -39.21% | Truist Securities | Joon Lee75% | $36 → $42 | Maintains | Buy | Get Alert |
| 01/02/2024 | Buy Now | -59.47% | HC Wainwright & Co. | Swayampakula Ramakanth47% | $34 → $28 | Maintains | Buy | Get Alert |
| 12/13/2023 | Buy Now | -45% | Canaccord Genuity | Edward Nash61% | $37 → $38 | Maintains | Buy | Get Alert |
| 11/06/2023 | Buy Now | -45% | Truist Securities | Joon Lee75% | $29 → $38 | Upgrade | Hold → Buy | Get Alert |
| 11/02/2023 | Buy Now | -50.79% | HC Wainwright & Co. | Swayampakula Ramakanth47% | $32 → $34 | Maintains | Buy | Get Alert |
| 10/02/2023 | Buy Now | -58.03% | Truist Securities | Joon Lee75% | → $29 | Reiterates | Hold → Hold | Get Alert |
| 08/25/2023 | Buy Now | -49.34% | Canaccord Genuity | Edward Nash61% | $34 → $35 | Maintains | Buy | Get Alert |
| 08/03/2023 | Buy Now | -55.13% | Piper Sandler | David Amsellem69% | $27 → $31 | Maintains | Overweight | Get Alert |
| 08/03/2023 | Buy Now | -58.03% | Truist Securities | Gregory Fraser64% | $26 → $29 | Maintains | Hold | Get Alert |
| 08/03/2023 | Buy Now | -53.68% | HC Wainwright & Co. | Swayampakula Ramakanth47% | $30 → $32 | Maintains | Buy | Get Alert |
| 05/26/2023 | Buy Now | -62.37% | Truist Securities | Gregory Fraser64% | $28 → $26 | Maintains | Hold | Get Alert |
| 05/04/2023 | Buy Now | -56.58% | HC Wainwright & Co. | Swayampakula Ramakanth47% | $30 → $30 | Reiterates | → Buy | Get Alert |
| 04/11/2023 | Buy Now | -63.82% | SVB Leerink | Roanna Ruiz34% | → $25 | Initiates | → Market Perform | Get Alert |
| 04/04/2023 | Buy Now | -60.92% | Piper Sandler | David Amsellem69% | → $27 | Initiates | → Overweight | Get Alert |
| 03/08/2023 | Buy Now | -53.68% | Canaccord Genuity | Edward Nash61% | $33 → $32 | Maintains | Buy | Get Alert |
| 03/01/2023 | Buy Now | -56.58% | HC Wainwright & Co. | Swayampakula Ramakanth47% | → $30 | Reiterates | → Buy | Get Alert |
| 02/15/2023 | Buy Now | -68.16% | Jefferies | Dennis Ding16% | $35 → $22 | Downgrade | Buy → Hold | Get Alert |
| 12/09/2022 | Buy Now | -56.58% | HC Wainwright & Co. | Swayampakula Ramakanth47% | $33 → $30 | Maintains | Buy | Get Alert |
| 11/08/2022 | Buy Now | -59.47% | Truist Securities | Gregory Fraser64% | $30 → $28 | Maintains | Hold | Get Alert |
| 08/04/2022 | Buy Now | -52.24% | HC Wainwright & Co. | Swayampakula Ramakanth47% | $29 → $33 | Maintains | Buy | Get Alert |
| 08/01/2022 | Buy Now | -56.58% | Truist Securities | Gregory Fraser64% | → $30 | Downgrade | Buy → Hold | Get Alert |
FAQ
What is the target price for Corcept Therapeutics (CORT) stock?
The latest price target for Corcept Therapeutics (NASDAQ:CORT) was reported by Piper Sandler on April 3, 2025. The analyst firm set a price target for $131.00 expecting CORT to rise to within 12 months (a possible 89.61% upside). 24 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Corcept Therapeutics (CORT)?
The latest analyst rating for Corcept Therapeutics (NASDAQ:CORT) was provided by Piper Sandler, and Corcept Therapeutics maintained their overweight rating.
When was the last upgrade for Corcept Therapeutics (CORT)?
The last upgrade for Corcept Therapeutics Inc happened on November 6, 2023 when Truist Securities raised their price target to $38. Truist Securities previously had a hold for Corcept Therapeutics Inc.
When was the last downgrade for Corcept Therapeutics (CORT)?
The last downgrade for Corcept Therapeutics Inc happened on February 15, 2023 when Jefferies changed their price target from $35 to $22 for Corcept Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Corcept Therapeutics (CORT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Corcept Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Corcept Therapeutics was filed on April 3, 2025 so you should expect the next rating to be made available sometime around April 3, 2026.
Is the Analyst Rating Corcept Therapeutics (CORT) correct?
While ratings are subjective and will change, the latest Corcept Therapeutics (CORT) rating was a maintained with a price target of $128.00 to $131.00. The current price Corcept Therapeutics (CORT) is trading at is $69.09, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.